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Abstract
Background:  Transforming growth factor β1 (TGFβ1) is a potent inhibitor of epithelial cell
growth, thus playing an important role in tissue homeostasis. Most carcinoma cells exhibit a
reduced sensitivity for TGFβ1 mediated growth inhibition, suggesting TGFβ1 participation in the
development of these cancers. The tumor suppresor gene DPC4/SMAD4, which is frequently
inactivated in carcinoma cells, has been described as a key player in TGFβ1 mediated growth
inhibition. However, some carcinoma cells lacking functional SMAD4 are sensitive to TGFβ1
induced growth inhibition, thus requiring a SMAD4 independent TGFβ1 pathway.
Results: Here we report that mature TGFβ1 is a ligand for the integrin αVβ6, independent of the
common integrin binding sequence motif RGD. After TGFβ1 binds to αVβ6 integrin, different
signaling proteins are activated in TGFβ1-sensitive carcinoma cells, but not in cells that are
insensitive to TGFβ1. Among others, interaction of TGFβ1 with the αVβ6 integrin resulted in an
upregulation of the cell cycle inhibitors p21/WAF1 and p27 leading to growth inhibition in SMAD4
deleted as well as in SMAD4 wildtype carcinoma cells.
Conclusions: Our data provide support for the existence of an alternate TGFβ1 signaling pathway
that is independent of the known SMAD pathway. This alternate pathway involves αVβ6 integrin and
the Ras/MAP kinase pathway and does not employ an RGD motif in TGFβ1-sensitive tumor cells.
The combined action of these two pathways seems to be necessary to elicit a complete TGFβ1
signal.
Background
The normal function of transforming growth factor β1
(TGFβ1) is essential for the entire organism, representing
a multifunctional regulator of cell growth and differentia-
tion [1–5]. TGFβ1 is a potent inhibitor of epithelial cell
proliferation. Upon binding of TGFβ1, TGFβ1-receptors
phosphorylate SMAD2 or SMAD3 [6–12]. Phosphor-
ylated SMAD2/3 associates with SMAD4 and, as a com-
plex, moves into the nucleus, where it regulates gene
expression [13–15].
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SMAD4 (DPC4) is essential for this TGFβ1 signaling and
transcriptional activation process [16]. In epithelial cells,
TGFβ1 decreases c-myc, cdc2 and cyclin D1 expression,
and it increases the expression of c-jun and c-fos [17–23].
Activation of the TGFβ1 signal pathway in epithelial cells
leads to an increased expression of the cell cycle inhibitors
p21WAF1 and p15Ink4b and to a release of formerly seques-
tered p27KIP [24–26]. It is assumed that the cooperative
action of these cell cycle inhibitors results in the growth
arrest mentioned above, although p15Ink4b does not seem
to be necessary in this regard. In addition to mutations in
the TGFβ1-receptors, in a large number of carcinomas dis-
ruptions of this signaling pathway by the alteration of a
single protein such as p15Ink4b, p16, and p21Waf1  are
found [2,27–39]. This may result in resistance to the
growth-inhibiting action of TGFβ1.
In several cell lines, particularly in pancreatic carcinoma
cells, resistance to TGFβ1 could be attributed to a loss of
function of the SMAD4 (DPC4) protein [40–43]. How-
ever, the pancreatic carcinoma cell line BxPC-3, although
homozygously deleted for SMAD4, is growth inhibited by
TGFβ1 [30,44]. It is thus speculated that alternative signal-
ing pathways in addition to the SMAD pathway may exist.
After binding to αVβ6 integrin, latent TGFβ1 is activated by
processing of latent TGFβ1 by cleavage of the latency-asso-
ciated Peptide (LAP) [45–57]. Recently, the interaction of
latent TGFβ1 with αVβ6 integrin has been shown [45]. After
binding of latent TGFβ1 to αVβ6 integrin, latent TGFβ1 is
activated by cleavage of the latency-associated peptide
(LAP) [45]. This αVβ6 integrin is also expressed by pancre-
atic carcinoma cells [58–63]. We hypothesized that there
is a SMAD-independent TGFβ1  signaling pathway in
TGFβ1-sensitive carcinoma cells. To address this question,
several carcinoma cell lines with different degrees of
TGFβ1 sensitivity were chosen as a model system. We
investigated the interaction of TGFβ1  with the αVβ6
integrin and its influence on selected target genes known
to be involved in cell cycle-regulated growth inhibition.
Here, we demonstrate an alternate TGFβ1 signaling path-
way via αVβ6  integrin contributing to TGFβ1  growth
inhibiton in TGFβ1 sensitive carcinoma cells.
Results
Mature TGFβ1 induces cytoskeletal immobilization of 
proteins and tyrosine phosphorylation via integrin αVβ6 
only in TGFβ1 sensitive cells
Only integrins that have bound their ligands are anchored
to the cytoskeleton [64,65]. In our experiments, mature
TGFβ1, αVβ6 integrin, and F-actin colocalize (Figure 1),
suggesting association with and activation of this integrin.
To further support this finding, we stimulated cells and
performed co-immunoprecipitated various integrin subu-
nits of cytoskeletal anchored proteins [66,67] (additional
file 1, 2, 3 and 4). Our data strongly suggest that mature
TGFβ1 associates with αVβ6 integrin (additional file 1, 2, 3
and 4).
To determine whether binding of mature TGFβ1 leads to
integrin-mediated signaling, we looked at the status of
integrin-cytoskeleton-associated proteins [66,67] after
incubation with mature TGFβ1 in selected carcinoma cell
lines with different degrees of sensitivity to TGFβ1 (Table
1). Cytoskeletal anchored proteins were precipitated with
anti αV and β6-antibodies. Immobilization of proteins to
the cytoskeleton (Triton-X insoluble fraction, Figure 2B)
as well as tyrosine phosphorylation of these proteins (Fig-
ure 2A) induced through mature TGFβ1 was only seen in
the TGFβ1-sensitive carcinoma cell lines (Figure 2 and
additional file 5). Notably, tyrosine phosphorylation of
cytoskeletally anchored proteins is further enhanced after
combined treatment with mature TGFβ1 and fibronectin
in TGFβ1 sensitive cells (Figure 3). In contrast, in the
TGFβ1-resistant AsPC-1 and Capan-1 cells, the interaction
of mature TGFβ1 with αVβ6 integrin resulted in an immo-
bilization of high molecular weight proteins to the
cytoskeleton without tyrosine phosphorylation (Figure
2). Again, stimulation of TGFβ1 sensitive cells BxPC-3,
LoVo [68], SW48 [68], Keratinocytes, HeLa and DLD1
[69], results in an enhanced cytoskeletal immobilization
and tyrosine phosphorylation of cellular proteins in
response to stimulation with mature TGFβ1 (additional
file 5). Remarkably, preincubation with the MEK1 inhibi-
tor PD98059 resulted in a reduced cytoskeletal immobili-
zation and tyrosine phosphorylation of cellular proteins
in response to stimulation with mature TGFβ1. This find-
ing is in agreement with other observations that MEK1-
mediated signal transduction is involved in cytoskeletal
remodeling and integrin engagement [70,71].
Activation of p125FAK, a central step in integrin-associated
signaling [72,73], was determined to assess integrin-medi-
ated signaling. BcPC-3 cells are sensitive to TGFβ1 but are
SMAD4 deleted. We incubated BxPC-3 cells with mature
TGFβ1 and observed an association on the cytoskeleton
connected with integrin αVβ6 and activation of p125FAK
(Figure 4). Indeed, TGFβ1 antibodies, cytochalasin D and
BAPTA-AM [66] abolished the association on the cytoskel-
eton connected with integrin αVβ6  and activation of
p125FAK. These data further suggest that TGFβ1 mediated
activation of p125FAK depends on free intracellular cal-
cium and an intact actin cytoskeleton.
In order to test whether TGFβ1 signaling via αVβ6 is specific
for SMAD4 deleted BxPC-3 cells or if this is a general phe-
nomenon, we investigated signaling in TGFβ1-sensitive
carcinoma cell lines HeLa, MCF-7 and MDA-MB-231.
TGFβ1 induced recruitment of p125Fak, p130Cas and Sos1/
2 to the cytoskeleton. Enhanced expression of c-jun, c-fos,Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/28
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p21WAF1  and p27KIP, while downregulating PCNA, is
dependent on ERK1/2 signaling, an intact cytoskeleton
and intracellular calcium (Figures 5, 6A, 7, 8 and addi-
tional files 6, 7 and 8). We also confirmed the purity of the
commercially available mature TGFβ1 used in these exper-
iments by silver stained non-reducing SDS-PAGE, with
latent TGFβ1 as control (Figure 6B). We also demonstrated
the SMAD4 deficiency of the BxPC-3 cells used (Figure
6C).
TGFβ1/αVβ6 integrin signaling is independent of the known 
TGFβ1 signaling pathway
To explain the TGFβ1 sensitivity of SMAD4-deleted cells, it
is speculated that after binding of TGFβ1 to its receptor,
Colocalization of TGFβ1, αVβ6 integrin and the cytoskeleton Figure 1
Colocalization of TGFβ1, αVβ6 integrin and the cytoskeleton. Panc-1 cells were stimulated with mature TGFβ1 and 
stained using anti TGFβ1 (labeled with goat anti-rabbit IgG conjugate, A-11046), αV/β6 (labeled with goat anti-rabbit IgG conju-
gate, A-11046) and Actin antibodies. Magnification 1000×.
Table 1: SMAD4 status and TGFβ1 response of selected tumor cell lines were: (1) confirmed by PCR sequencing (data not shown) and 
(2) by [3H] thymidine incorporation assays (data not shown). WT denotes wild type.
Cell lines Smad4 status1 Growth inhibition2 by TGFβ1
Panc-1 + (WT) +
BxPC-3 - (homozygous deleted) +
Capan-1 - (frame shift mutation) -
AsPC-1 - (amino acid replacement) -
HeLa + (WT) +
MCF-7 + (WT) +
MDA-MB-231 + (WT) +
Actin
αVβ6
TGFβ1
+ TGFβ1 -T G F β1
Actin αVβ6
TGFβ1
αVβ6 Actin
Actin
αVβ6
TGFβ1
TGFβ1Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/28
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activated SMAD2/3 may translocate to the nucleus and
activate gene expression even in the absence of SMAD4.
To exclude this possibility, cellular proteins were divided
into cytoplasmatic and nuclear fractions after TGFβ1 stim-
ulation, and localization and phosphorylation of
SMAD2/3 were investigated. In the SMAD4 deleted BxPC-
3 cells, TGFβ1 resulted in phosphorylation of SMAD2/3,
but the activated SMAD proteins were retained in the cyto-
plasmatic fraction (Figure 9). Remarkably, in NP-9 cells
[74], SMAD2/3 are translocated into the nucleus upon
TGFβ1 stimulation (additional file 9(A)) but we could not
observe an enhanced tyrosine phosphorylation of
cytoskeletal anchored proteins (additional file 9(B)).
TGFβ1 mediated growth inhibition is dependent on αVβ6 
integrin
Influence of TGFβ1 on cell growth is well established, but
the mechanisms are not fully understood [75–79]. Here,
we assayed for the possible synergistic function of αVβ6
integrin on mature TGFβ1 mediated growth inhibition in
Panc-1 cells. As shown in the additional file 10, combined
treatment with αV and β6 blocking antibodies almost com-
pletely abolished the effect of mature TGFβ1  on the
growth of Panc-1 cells. We therefore postulate that the
growth inhibition of TGFβ1 is synergistically influenced
by αVβ6 integrin.
Discussion
A recent study demonstrated an interaction of latent
TGFβ1 with αVβ6 integrin, which led to an activation of
latent TGFβ1 [45]. Incubation of different tumor cells with
mature TGFβ1 resulted in a direct binding of TGFβ1 to αVβ6
integrin. Certain integrins appear to be preferentially asso-
ciated with specific growth factor receptors [80]. The inter-
action of these two receptor classes seems to take place via
the actin cytoskeleton. We were able to exclude such sig-
nal pathway association, since in our cytoskeletal prepara-
tions, no TGFβ1-receptors were detectable, indicating that
mature TGFβ1 is a ligand for αVβ6.
It has been reported that activated integrins are associated
with the cytoskeleton. Here, we show that binding of
mature TGFβ1 to αVβ6 integrin resulted in an association
of the cytoskeleton (Figure 10). In a variety of integrin-
mediated signaling pathways, tyrosinephosphorylation of
proteins immobilized to the cytoskeleton is enhanced
[66,67]. The same was true in our experimental settings
only for the TGFβ1-sensitive cells. This upregulation of
Phosphorylation and immobilization of proteins associated  with the integrin-cytoskeleton-complex Figure 2
Phosphorylation and immobilization of proteins asso-
ciated with the integrin-cytoskeleton-complex. 
Cytoskeletally anchored αVβ6 was immunoprecipitated after 
TGFβ1 stimulation (10 nM for 10 minutes) followed by West-
ern analysis with antibodies against tyrosine-phosphorylated 
proteins (A) or Western blotting after biotinylation of all 
proteins and streptavidin detection (B). Presence of TGFβ1 
(C), αV and β6 integrin (D) in the co-precipitates is also dem-
onstrated. TGFβ-receptor-I and II (TGFβRI and TGFβRII) are 
expressed at nearly equal levels in all cell lines as demon-
strated by western blotting from whole cell extracts (E). In 
part the cells were preincubated with αV- and β6-antibodies 
(1:100 each for 30 min) or with a TGFβ antibody (15 µg/ml 
for 30 min).
-+++-+ ++-+++ -+ ++T G F β1
+- +- +- +- T G F β1 antibody
-+ -+ -+ -+ αVa n dβ6 antibody
A
B
C
Panc-1 AsPC-1 BxPC-3 Capan-1
130 kDa
130 kDa
90 kDa
90 kDa
TGFβ1
D
TGFβRI
TGFβRII
Panc-1 AsPC-1 BxPC-3 Capan-1
- +-+ -+ -+ T G F β1
αV
β6
E
Enhanced Tyrosine Phosphorylation of proteins associated  with the integrin-cytoskeleton-complex Figure 3
Enhanced Tyrosine Phosphorylation of proteins asso-
ciated with the integrin-cytoskeleton-complex. 
Cytoskeletally anchored αVβ6 was immunoprecipitated after 
TGFβ1 and/or fibronectin stimulation (10 nM for 10 minutes) 
followed by Western analysis with antibodies against tyro-
sine-phosphorylated proteins (A). Reprobing with αV and β6 
antibodies show equal anounts of precipitates used (B).
-+ - +-+-+-+-+ - +- + T G F β1
+ + + + + + + + Fibronectin
ASPC-1 BXPC-3 Capan-1 Panc-1
180 kDa
130 kDa
100 kDa
80 kDa
65 kDa
50 kDa
αV
β6
A
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tyrosine phosphorylation was inhibited by preincubation
with a TGFβ1 neutralizing antibody or by blocking of αVβ6
integrin, thus again proving mature TGFβ1 as an initial sig-
naling ligand for αVβ6.
Binding of mature TGFβ1 to αVβ6 integrin exerts several
downstream effects in TGFβ1-sensitive cells (Figure 9).
One is a marked phosphorylation of p125FAK. This phos-
phorylation is dependent on the integrity of the cytoskel-
eton, as disruption of actin filaments by cytochalasin D
completely eliminated this effect, findings which have
also been reported for several integrin signaling pathways
[66,67]. Moreover, incubation of the TGFβ1 sensitive car-
cinoma cells with TGFβ1 caused immobilization of the
docking protein p130cas and of the guanine nucleotide
exchange factor SOS to the cytoskeleton. Beyond this, a
marked induction of the cell cycle inhibitors p21WAF1 and
p27KIP and a decrease in PCNA expression was detectable.
Finally, TGFβ1 caused an activation of p21Ras and the
MAP kinases ERK1 and ERK2. This TGFβ1-induced
expression profile was not affected by preincubation of
SMAD4 deleted BxPC-3 cells with a TGFβ1-RII blocking
antibody, which was able to completely block TGFβ1-
induced SMAD2/3 phosphorylation, thus demonstrating
the independence of the TGFβ1-signaling from the known
SMAD pathway in BxPC-3 cells. In contrast, preincuba-
tion with αV- and β6-blocking antibodies curbed the
TGFβ1-induced regulation of p21/WAF1, p27, c-fos, and
the p21Ras and ERK1/2 activation, verifying that the bind-
ing of TGFβ1 to the αVβ6 integrin is a prerequisite for the
activation of the signal pathway via the αVβ6 integrin. Pre-
incubation of the cells with the MEK1 inhibitor PD98059
curbed the TGFβ1-induced regulation of these genes as
well, indicating the involvement of the MAP kinase path-
way in TGFβ1 signaling in BxPC-3 cells. As shown recently,
the growth-stimulatory effect of the TGFβ superfamily
member BMP-2on CAPAN-1 cells was blocked by this
inhibitor as well [81–83], supporting our findings.
Indeed, cytoskeletal immobilization of p130cas and SOS
was not prevented by the MEK1 inhibitor PD 98059.
Thus, these proteins are good candidates to link the
integrin-mediated TGFβ1  signaling to the MAP kinase
pathway, as was shown previously for signaling events
induced by fluid stress or integrin mediated cell-adhesion
in other cell types [71,84–91].
In order to generalize the integrin mediated TGFβ1-path-
way identified in the SMAD4 deleted pancreatic tumor
cell line BxPC-3, we investigated TGFβ1 signaling in the
cervical carcinoma cell line HeLa and the mammary carci-
noma cell lines MCF-7 and MDA-MB-231, harboring a
wildtype SMAD4-gene. TGFβ1 bound to αVβ6-integrin in
these cells as well, and this interaction resulted both in an
immobilization of p130Cas and SOS1/2 and in tyrosine
phosphorylation of cytoskeleton-associated proteins such
as p125FAK. TGFβ1 stimulation of these cells acvtivated
p21Ras and MAPK ERK1/2, upregulated c-fos, c-jun/AP1,
p21/WAF1 and p27 expression, and resulted a decrease of
PCNA, similar to its actions in BxPC-3 cells. Preincuba-
tion with a TGFβ-RII blocking antibody attenuated the
TGFβ1 induced pattern, contrary to SMAD 4 deleted BxPC-
3 cells. This preincubation also decreased activation of
p21Ras and of MAPK ERK1/2, indicating the participation
of the Ras/MAPK-pathway in TGFβ1 induced transcrip-
tional activation.
The same attenuation of TGFβ1 induced gene expression
and the decrease in p21Ras and MAPK ERK1/2 activation
was observable after preincubation of SMAD4 wildtype
cells with αVβ6-blocking antibodies, demonstrating that
TGFβ1 signaling via αVβ6-integrin also is linked to the Ras/
MAPK-pathway, and that both pathways have synergistic
effects in TGFβ1-signaling. Full TGFβ1 induced transcrip-
tional activation is only reached if both pathways are
completed. This finding is supported by the observation
that activation of p21/Ras and MAPK ERK1/2 induced by
TGFβ1 is only reverted to the control level by the combina-
tion of the TGFβ-RII blocking antibody and the αVβ6-
blocking antibodies, or by inhibition of MEK1.
Linking of the TGFβ-R pathway to the Ras/MAPK pathway
is dependent on a functional SMAD4 gene product,
because TGFβ1 induced gene expression and activation of
Ras and ERK1/2 is attenuated by the TGFβ-RII blocking
antibody only in SMAD4 wild type cells, whereas in the
p125FAK activation by mature TGFβ1 via integrin αVβ6 Figure 4
p125FAK activation by mature TGFβ1 via integrin 
αVβ6. Stimulation of BxPC-3 with mature TGFβ1 (10 nM for 
10 minutes), immunoprecipitation with αV- and β6 integrin 
antibodies after preparation of the cytoskeleton, followed by 
probing with pp125Fak and p125FAK antibodies. In part the 
cells were preincubated with αV- and β6-antibodies (1:100 
each for 30 min), with a TGFβ antibody (15 µg/ml for 30 
min), cytochalasin D and BAPTA AM, respectively.
pp125FAK
+ + 10% FCS
-+--+--++--++ - T G F β1
+ + + + - - - - 5µM BAPTA-AM
-- - -+ ++ + 25nM Cytochalasin D
+ - - + TGFβ1 antibody
p125FAKMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/28
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Cell cycle genes in response to TGFβ1 Figure 5
Cell cycle genes in response to TGFβ1. Western Blot analysis of HeLa cells stimulated with 10 nM of mature TGFβ1 for 
the time indicated. Cytoskeletally anchored proteins are differentially marked. In part the cells were preincubated with αV- and 
β6-antibodies (1:100 each for 30 min), with a TGFβ-RII antibody (15 µg/ml for 30 min), cytochalasin D, BAPTA AM and MEK1 
inhibitor PD98059, respectively.
- + ++++ T G F β1
p130CAS
Sos1/2
p125FAK
PCNA
Cyclin E
p21WAF1
p27KIP
c-fos
c-jun
+- +-αVβ6 antibody
+ + - TGFβ1 RII antibody
+ MEK1 inhibitor
p21Ras*
ERK1/2-P
HeLa
10 min
6 hMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/28
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SMAD4 deleted BxPC-3 cells, no such influence was
observable.
Based on our results, we suggest the following model of
TGFβ1-signaling, which offers an explanation for the
different growth responses to TGFβ1  (Fig. 10). In the
TGFβ1-sensitive cell lines with intact SMAD pathway, the
TGFβ1 response can be attributed to both the common
SMAD signaling pathway and the integrin pathway
described above. In the cell line BxPC-3, lacking the
SMAD4 gene product, the SMAD4-independent pathway
can explain the TGFβ1 sensitivity via αVβ6 integrin, the
cytoskeleton and the Ras/MAP kinase pathway, resulting
in an upregulation of the cell cycle inhibitiors p21/WAF1
and p27, which in turn results in the TGFβ1-induced
growth inhibition (additional file 10).
The cell lines Capan-1 and AsPC-1 are not only resistant
to TGFβ1 because of their alterations in the SMAD path-
way, but also because they cannot complete the alternate
pathway, as demonstrated above. Furthermore, this
alternate pathway may explain the TGFβ1 resistance of
cells with no detectable defect in the SMAD pathway [92–
101], as one can imagine that the cooperative action of the
Enhanced level of cytoskeletal anchored proteins in response to TGFβ1 (A) Figure 6
Enhanced level of cytoskeletal anchored proteins in response to TGFβ1 (A). Western Blot analysis of BxPC-3 and 
HeLa cells as indicated after stimulation with TGFβ1 for the time indicated. Cytoskeletally anchored proteins are differentially 
marked. In part the cells were preincubated with αV- and β6-antibodies (1:100 each for 30 min), with a TGFβ-RII antibody (15 
µg/ml for 30 min), cytochalasin D, BAPTA AM and MEK1 inhibitor PD98059, respectively. Purity of the TGFβ1 used (B). 
Ten nanogram of mature TGFβ1 and latent TGFβ1 were subjected to non-reducing SDS-PAGE dollowed by silver staining. No 
latant TGFβ1 could be detected in the mature TGFβ1 used for stimulation. BxPC-3 cells are SMAD4-/-(C). One hundred 
microgram of whole cell extract from BxPC-3 and HeLa cells were probed with p125FAK and SMAD4 antibodies on the same 
membrane. As reported, BxPC-3 cells are found to be SMAD4-/-.
TGFβ1 - ++ + + - +++++
TGFβ1 RII antibody + + +
αVβ6 antibody  + +
MEK1 inhibitor + +
p130Cas
SOS1/2
pp125FAK
BxPC-3 HeLa
mature TGF-β1
latent TGF-β1
-+
+-
latent TGF-β1
mature TGF-β1
A
B
B
x
P
C
-
3
H
e
L
a
p125FAK
SMAD4
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Cell cycle genes in response to TGFβ1 Figure 7
Cell cycle genes in response to TGFβ1. Western Blot analysis of MCF-7 and MDA-MB 231 cells as indicated after stimula-
tion with TGFβ1 for the time indicated. Cytoskeletally anchored proteins are differentially marked. In part the cells were prein-
cubated with αV- and β6-antibodies (1:100 each for 30 min), with a TGFβ-RII antibody (15 µg/ml for 30 min), cytochalasin D, 
BAPTA AM and MEK1 inhibitor PD98059, respectively.
-+ + + + + T G F β1- + + + + +
++ T G F β1-RII antibody + +
++ αVβ6 antibody + +
+ MEK1 inhibitor +
MCF-7 MDA-MB 231
p21Ras*
ERK 1/2-P
c-jun
c-fos
p21WAF1
p27Kip
PCNA
130 kDa
90 kDa
p-Y
10 min
6 h
10 minMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/28
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both pathways is necessary to exert the complete growth
inhibitory effect of TGFβ1. Comparable effects have been
described for the synergistic operation of growth factor
receptor and anchorage dependent integrin signaling
[102–119].
Recombinant mature TGFβ1  does not contain a RGD
motif, and thus binding of TGFβ1 to the αVβ6 integrin and
the subsequent activation of this integrin must rely on a
novel motif distinct from RGD. For αVβ6 integrin, a novel
non-RGD ligand recognition motif was recently described
with the consensus motif DLXXL [120].
This motif has been detected on several proteins, includ-
ing laminin, collagen and fibrinogen [120]. A BLAST
search for this sequence in TGFβ1 revealed a 70% similar
motif in two parts of the molecule; one in the LAP (data
not shown) and one in the mature TGFβ1. In mature
TGFβ1, the DLXXL motif is freely accessible for interac-
tions on the outside of the molecule. Therefore, it may be
speculated that TGFβ1 binding to αVβ6 via this novel lig-
and recognition motif is facilitating the signaling.
Moreover, a non-RGD ligand binding pocket in addition
to the usual RGD binding site has been demonstrated for
fibrinogen and the αIIbβ3 integrin [121], supporting our
findings.
Conclusions
We demonstrate an alternate TGFβ1 signaling pathway via
αVβ6  integrin, independent of SMAD4. This pathway
Cell cycle genes in response to TGFβ1 Figure 8
Cell cycle genes in response to TGFβ1. Western Blot analysis of BxPC-3, LOVO, SW48 and DLD1 cells as indicated after 
stimulation with TGFβ1 for the time indicated. Cytoskeletally anchored proteins are differentially marked. In part the cells were 
preincubated with αV- and β6-antibodies (1:100 each for 30 min), with a TGFβ-RII antibody (15 µg/ml for 30 min), cytochalasin 
D, BAPTA AM and MEK1 inhibitor PD98059, respectively.
TGFβ1 - ++++ - ++++ - ++++ - ++++
BxPC-3 LoVo SW48 DLD1
TGFβ1 RII antibody + + + +
αVβ6 antibody + + + +
MEK1 inhibitor + + + +
p21Ras*
pp125FAK
c-jun
p21WAF1
p27KIP
PCNA
p130Cas
ERK1/2-P
10 min
6 hMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/28
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seems to be required for full TGFβ1  induced
transcriptional activation, which explains the TGFβ1 sensi-
tivity of those cells lacking DPC4/SMAD4 function that
still react with growth inhibition.
Methods
Cell Culture and TGFβ1 stimulation
All cells were obtained from from ATCC and maintained
in DMEM supplemented with 17% fetal calf serum.
Recombinant human proteins (mature TGFβ1, TNF-α,
Fibronectin and Laminin 1) were purchased from R&D
Systems. 106 cells were grown overnight in 6 cm diameter
dishes with DMEM/10 % FCS. After washing twice with
PBS (pH 7.4), fresh DMEM without FCS was added to the
monolayer. Cells were stimulated with 10 nM of mature
TGFβ1 or with fibronectin as described below. In blocking
experiments, cells were preincubated with either a TGFβ1-
RII-blocking antibody (R&D Systems # AF-241-NA, 15 µg/
ml for 30 min), αV and  β6-blocking antibodies (Santa
Cruz, sc-6617 and sc-6632 respectively, 1:100 each for 30
min), or the MEK1 inhibitor PD98059 (New England
Biolabs # 9900S, 7.5 ng/ml for 10 min) before stimula-
tion with mature TGFβ1.
Indirect immunofluorescence
For indirect immunofluorescence, 104 cells were cultured
on glass coverslips, stimulated with 10 nM mature TGFβ1
for 10 minutes, stained as described [66,67] and viewed
using a Zeiss LSM-510 confocal microscope. Antibodies
used were: actin (sc-8432), TGFβ1 (sc-146), αV (sc-6617)
and  β6  (sc-6632). The following fluorochrome-labeled
antibodies were used (AlexaFluor, Molecular Probes):
Activation and nuclear translocation of SMAD2/3 in response to TGFβ1 (A) Figure 9
Activation and nuclear translocation of SMAD2/3 in response to TGFβ1 (A). Nuclear and cytoplasmatic fraction of 
cellular proteins (BxPC-3) after stimulation with 10 nM of TGFβ1 for 10 minutes and Western blot analysis for SMAD2/3 and 
phosphorylated SMAD2/3. Purity of cytoplasmic and nuclear fraction (B). Cytoplasmic and nuclear extracts from K562 
cells were probed with p125FAK, PCNA and Iκ Bα antibodies at the same time. As predicted, p125FAK cold exclusively be 
detected in the cytoplasmic extract, whereas PCNA is found in the nucleus. Iκ Bα served as loading control.
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goat anti-mouse IgG (H+L) conjugate (#A-11032; red),
goat anti-rabbit IgG (H+L) conjugate (#A-11046; blue),
and donkey anti-goat IgG (H+L) conjugate (#A-11055;
green).
Preparation of cytoplasmatic proteins and of nuclei
Cellular fractionation was performed as described in ear-
lier reports [122–125]. Cells were scraped into 100 µl of
ice-cold buffer A [10 mM Hepes (pH 7.9); 1.5 mM MgCl2;
10 mM KCl; 0.5 mM DTT; 0.05% NP-40]. Nuclei were pel-
leted in a microcentrifuge for 10 sec. at 4°C and 15,000 G.
The supernatant was used to analyze cytoplasmatic pro-
teins, nuclei were resuspended in 60 µl of ice cold buffer
B [20 mM Hepes (pH 7.9); 25% (v/v) glycerol; 420 mM
KCl; 1.5 mM MgCl2; 0.2 mM EDTA; 0.5 mM DTT; 0.5 mM
PMSF] and incubated on ice for 15 min.
Preparation of actin filaments of the cytoskeleton and 
immunoprecipitation
The cell monolayer was incubated with cell extraction
buffer [0.1 % Triton X-100, 80 mM KCl, 20 mM imida-
zole, 2 mM MgCl2, 2 mM EGTA, pH 7.8] for 5 min at 4°C.
The Triton-insoluble fractions were then scraped into cold
Triton X-100 lysis buffer [50 mM Tris/HCl (pH 7.4); 100
mM NaCl; 50 mM NaF; 5 mM EDTA; 40 mM glycerophos-
phate; 1 mM sodium orthovanadate; 100 µM PMSF; 1 µM
leupeptin; 1 µM pepstatin A; 1% (v/v) Triton X-100] and
incubated for 20 min on ice, and clarified by centrifuga-
tion at 13000 g for 5 min at 4°C. For
immunoprecipitation, the lysates were incubated for 4 h
at 4°C with 1 µg of antibody (all from Santa Cruz) pre-
adsorbed on Protein A-Sepharose beads (Pharmacia).
Immune complexes were washed five times with cold Tri-
ton X-100 lysis buffer. For re-precipitation, the pellet was
boiled in 10 µl 0.1% SDS for 5 min and diluted 1:20 in the
Triton X lysis buffer followed by the precipitation
procedure. All samples were boiled in Laemmli denatur-
ing buffer and analyzed by Western blotting. Whole cell
lysates serving as positive controls were prepared by incu-
bating monolayers with denaturing Laemmli buffer.
Treatment with Cytochalasin and Calcium Chelator
To disrupt the actin filaments of the cytoskeleton, the cell
monolayer was treated with 25 nM cytochalasin D for 20
min at 37°C; TGFβ1 was then applied in the presence of
25 nM cytochalasin D. For chelating intracellular calcium,
the cells were preincubated with 5 µM of 1,2-bis(2-ami-
nophenoxy)ethane-N,N,N',N'-tetraacetic acid,
acetoxymethyl ester (BAPTA-AM) for 15 min. TGFβ1 was
then applied in the presence of 5 µM of BAPTA.
[3H]-thymidine incorporation assay
For the TGFβeta1  growth inhibition assay, cells were
seeded in 96-well microtitier plates at 104 cells/well in 100
µl of culture medium containing 10% FCS. After 24 h,
medium was replaced by culture medium supplemented
with 0.5% FCS. After an additional 24 h, cells were treated
with 10 nM of mature TGFβ1. After incubation with TGFβ1
for 21 h, cells were pulsed with 200 nCi of [3H]-thymidine
(1.74 TBq/mmol; Amersham, UK) for 3 h without
changing the medium. Cells were washed once with PBS,
incubated with trypsin for 10 min and collected by using
a Skatron cell harvester. Radioactivity incorporated was
determined by liquid scintillation counting.
Western Blot
Proteins were separated by SDS-PAGE and transferred to a
polyvinylidene difluoride membrane (Roche) as
described previously [66]. Blot membranes were blocked
for 3 h at 37°C in PBS containing 5 % skim milk and
probed with the respective antibodies (16 h at 4°C). The
following antibodies were used in a dilution of 1:1,000:
TGFβ1  (Santa Cruz [sc], sc-146), p-Tyr (sc-7020), β6-
integrin (sc-6632), αV-integrin (sc-6617), p125FAK  (sc-
557), TGFβ1-RI (sc-402), TGFβ1-RII (sc-400-G), ERK1/2-P
(sc-7383), SMAD2/3 (sc-6033), SOS1/2 (sc-259), p130cas
(UBI-06-500), PCNA (sc-56), p21WAF1 (sc-6246), p27KIP
(sc-1641), c-fos (sc-7202), c-jun (sc-44), raf1 (sc-133),
p21Ras (sc-35) and phospho-threonine antibody (New
England Biolabs, # 9381). Detection antibodies (all from
Dako; 1:5,000 for 1 h at room temperature) were mouse-
anti-goat Ig, mouse-anti-rat Ig, rabbit-anti-mouse Ig, and
porcine-anti-rabbit Ig-HRP [66]. To visualize all trans-
ferred proteins, we used the ECL protein biotinylation
labeling modules (RPN 2202, Amersham) and streptavi-
din alkaline phosphatase (V020402, Amersham) in
accordance with the manufacturer's instructions.
Hypothesis about an alternate TGFβ1 signaling pathway via  αVβ6 integrin, independent of RGD Figure 10
Hypothesis about an alternate TGFβ1 signaling path-
way via αVβ6 integrin, independent of RGD. This path-
way may be required for full TGFβ1 induced transcriptional 
activation, which explains the TGFβ1 sensitivity of those cells 
lacking DPC4/SMAD4 function that still react with growth 
inhibition.
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Ras activation assay
Only activated p21Ras is able to bind Raf1, leading to a
Raf1-translocation to the cell membrane. After stimula-
tion with 10 nM mature TGFβ1 for 10 minutes, cells were
incubated in sterile water until they lysed. The membrane
fraction was lysed in Triton X-100 lysis buffer. Precipita-
tion against Raf1 and analysis for p21Ras followed.
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Additional File 1
Portable Network Graphic (PNG) File showing that mature TGFβ1 binds 
to αVβ6 integrin. The cells indicated were stimulated for ten minutes with 
10 nM of either mature TGFβ1, tumor necrosis factor α (TNFα) or 
fibronectin (FN). Cytoskeletal anchored proteins were extracted, co-
immunoprecipitated (IP) and analyzed (Blot) with the antibodies 
indicated.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-2-28-S1.png]
Additional File 2
Portable Network Graphic (PNG) File showing that mature TGFβ1 binds 
to αVβ6 integrin. The cells indicated were stimulated for ten minutes with 
10 nM of either mature TGFβ1, tumor necrosis factor α (TNFα), lam-
inin-1 (Lam1) or fibronectin (FN). Cytoskeletal anchored proteins were 
extracted, co-immunoprecipitated (IP) and analyzed (Blot) with the anti-
bodies indicated.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-2-28-S2.png]
Additional File 3
Portable Network Graphic (PNG) File showing that mature TGFβ1 binds 
to αVβ6 integrin and the speciticity of the signals detected as well. The cells 
indicated were stimulated for ten minutes with 10 nM of either mature 
TGFβ1, tumor necrosis factor α (TNFα), or fibronectin (FN). Cytoskele-
tal anchored proteins were extracted, co-immunoprecipitated (IP) and 
analyzed (Blot) with the antibodies indicated.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-2-28-S3.png]
Additional File 4
Portable Network Graphic (PNG) File showing the speciticity of the sig-
nals detected. The cells indicated were stimulated for ten minutes with 10 
nM of either mature TGFβ1, tumor necrosis factor α (TNFα), or fibronec-
tin (FN). Cytoskeletal anchored proteins were extracted, and analyzed 
(Blot) with secondary antibodies (α-mouse HRP plus α-rabbit HRP plus 
α-goat HRP conjugated antibodies.)
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-2-28-S4.png]
Additional File 5
Portable Network Graphic (PNG) File showing enhanced cytoskeletal 
immobilization and tyrosine phosphorylation of cellular proteins in 
response to stimulation with mature TGFβ1. Cytoskeletally anchored αVβ6 
was immunoprecipitated after TGFβ1 stimulation (10 nM for 10 min-
utes) followed by Western analysis with antibodies against tyrosine-phos-
phorylated proteins (A) or Western blotting after biotinylation of all 
proteins and streptavidin detection (B). In part the cells were preincu-
bated with αV- and β6-antibodies (1:100 each for 30 min) or with a 
TGFβ-RII antibody (15 µg/ml for 30 min).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-2-28-S5.png]
Additional File 6
Portable Network Graphic (PNG) File showing cell cycle genes in 
response to TGFβ1. Western Blot analysis of HeLa, MCF-7 and Keratino-
cytes (Keratino) cells as indicated after stimulation with TGFβ1 for the 
time indicated. Cytoskeletally anchored proteins are differentially marked. 
In part the cells were preincubated with αV- and β6-antibodies (1:100 
each for 30 min), with a TGFβ-RII antibody (15 µg/ml for 30 min), cyto-
chalasin D, BAPTA AM and MEK1 inhibitor PD98059, respectively.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-2-28-S6.png]
Additional File 7
Portable Network Graphic (PNG) File showing that PCNA regulation is 
dependent on αVβ6 integrins, intact cytoskeleton and free intracellular cal-
cium. BxPC-3 cells were stimulated with 10 nM of mature TGFβ1 for 6 
hours. In part the cells were preincubated with αV- and β6-antibodies 
(1:100 each for 30 min), with a TGFβ antibody (15 µg/ml for 30 min), 
cytochalasin D and BAPTA AM, respectively. Whole cell extract was 
probed with PCNA antibodies. Actin served as loading control.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-2-28-S7.png]
Additional File 8
Portable Network Graphic (PNG) File showing tha regulation of p27, 
p21, c-fos and c-jun are dependent on αVβ6 integrins, intact cytoskeleton 
and free intracellular calcium. BxPC-3 cells were stimulated with 10 nM 
of mature TGFβ1 for 6 hours. In part the cells were preincubated with αV- 
and β6-antibodies (1:100 each for 30 min), with a TGFβ-RII antibody 
(15 µg/ml for 30 min), cytochalasin D and BAPTA AM, respectively. 
Whole cell extract was probed with PCNA antibodies. Actin served as 
loading control.
Click here for file
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